Document is current
Any future updates will be listed below
-
Authors
Petitfils, Camille
Depommier, Clara
Delzenne, Nathalie M.
Everard, Amandine
Van Hul, Matthias
Cani, Patrice D.
-
Funding
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (T.0115.24)
Fonds De La Recherche Scientifique - FNRS (T.0032.25)
Walloon excellence in life sciences and biotechnology (WELBIO-CR-2022A-02P)
- License Information
-
More Information
Article History
Received: 19 March 2025
Accepted: 30 May 2025
First Online: 6 June 2025
Declarations
:
: Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee Commission d’Ethique Biomédicale Hospitalo-facultaire of the Université catholique de Louvain (Brussel, Belgium). The study was registered at as trial no. NCT02637115 (protocol code: 2015/02 JUL/369, approved on the 13 July 2015). Informed consent was obtained from all subjects involved in the study.
: Not applicable.
: PDC and AE are inventors on patent applications dealing with the use bacteria on metabolic disorders. PDC was co-founders of The Akkermansia company SA and Enterosys. A. E. and P.D.C. are inventors on patent applications dealing with gut microbes in food reward dysregulations. A.E. is inventor on patent applications dealing with the use of bacteria metabolites in the prevention or treatment of respiratory viral infections.
